Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies
Eli Lilly and Co. (NYSE:LLY) entered a strategic research collaboration and licensing agreement with privately held biotechnology company Stipple Bio Inc. on Monday to develop targeted cancer therapies. The agreement covers multiple drug targets and therapeutic approaches, with Stipple Bio eligible to receive up to $5.9 billion in milestone payments, along with royalties on potential product…
Eli Lilly and Co. (LLY) formed a strategic partnership with biotechnology firm Stipple Bio Inc. on Monday to develop advanced cancer therapies. The collaboration, aimed at creating precision treatments, will allow Stipple Bio to receive up to $5.9 billion in milestone payments and royalties on potential product sales, subject to achieving research, development, and commercialization milestones. Eli Lilly will secure exclusive global rights to manufacture and sell any therapies resulting from the partnership.
Utilizing its Pointillist Platform, Stipple Bio will identify novel binding molecules that target specific sites on tumor cell surfaces. Eli Lilly will integrate these discoveries with its own oncology technologies to create cancer treatments through various therapeutic approaches. The primary goal is to enhance treatment efficacy while minimizing harm to healthy tissue, addressing a significant issue in existing cancer drugs.
Stipple Bio's CEO, Jeff Landau, highlighted that Eli Lilly's expertise in oncology research and drug development would enhance the precision of cancer therapies. The partnership will enable Stipple Bio to broaden the platform's therapeutic applications while continuing its independent pipeline development.
In April, Stipple Bio secured $100 million in a Series A funding round to support early-stage clinical trials for its lead antibody-drug conjugate, STP-100, targeting solid tumors, including pancreatic cancer. The company recently ranked on The 2026 Endpoints 11, a list of promising privately-held biotech companies.
Eli Lilly, meanwhile, announced its acquisition of Calytrix Bio Inc. for up to $1.5 billion in cash. The deal includes an upfront payment to Calytrix shareholders and additional sums tied to clinical and regulatory milestones. Calytrix focuses on developing precision therapies for myeloproliferative neoplasms, blood cancers involving excessive blood cell production. Following the acquisition, Eli Lilly's shares fell by 1.17% to $1414.87 at the time of publication.
Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.